(Q42943351)

11 November 2017

title

Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension (English)

1 reference

11 November 2017

6

Pierre Fesler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20693396

18 June 2024

author name string

Benoit Rondelet

1

1 reference

11 November 2017

Laurence Dewachter

2

1 reference

11 November 2017

François Kerbaul

3

1 reference

11 November 2017

Céline Dewachter

4

1 reference

11 November 2017

Ives Hubloue

5

1 reference

11 November 2017

Stephane Franck

7

1 reference

11 November 2017

Myriam Remmelink

8

1 reference

11 November 2017

Serge Brimioulle

9

1 reference

11 November 2017

Robert Naeije

10

1 reference

11 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20693396

18 June 2024

publication date

6 August 2010

1 reference

full work available at URL

11 November 2017

http://intl-ajpheart.physiology.org/cgi/content/abstract/299/4/H1118

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20693396

https://www.physiology.org/doi/pdf/10.1152/ajpheart.00418.2010

18 June 2024

1 reference

https://api.crossref.org/works/10.1152/AJPHEART.00418.2010

American Journal of Physiology Heart and Circulatory Physiology

18 June 2024

published in

1 reference

11 November 2017

volume

299

1 reference

11 November 2017

issue

4

1 reference

11 November 2017

page(s)

H1118-23

1 reference

Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Single-beat estimation of right ventricular end-systolic pressure-volume relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Signaling molecules in nonfamilial pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Cellular and molecular basis of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00418.2010

Angiopoietin/Tie2 Pathway Influences Smooth Muscle Hyperplasia in Idiopathic Pulmonary Hypertension

21 January 2018

9

1 reference

https://api.crossref.org/works/10.1152/AJPHEART.00418.2010

The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects

18 June 2024

13

1 reference

https://api.crossref.org/works/10.1152/AJPHEART.00418.2010

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

18 June 2024

19

1 reference

https://api.crossref.org/works/10.1152/AJPHEART.00418.2010

Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension

18 June 2024

21

1 reference

https://api.crossref.org/works/10.1152/AJPHEART.00418.2010

Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension

18 June 2024

26

1 reference

https://api.crossref.org/works/10.1152/AJPHEART.00418.2010

18 June 2024

Identifiers

1 reference

11 November 2017

1 reference